![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Leroy V,1 Angus P,2 Bronowicki JP,3 Dore G,4 Hézode C,5 Pianko S,6 Pol S,7
Stuart K,8 Tse E,9 McPhee F,10 Bhore R,11 Jimenez-Exposito MJ,11 Thompson A4
1CHU de Grenoble, La Tronche, France; 2Austin Hospital, Heidelberg, Australia; 3CHU Nancy & Lorraine University, Nancy, France; 4St. Vincent's Hospital and Kirby Institute, Sydney, Australia; 5CHU Henri Mondor, Créteil, France; 6Monash Medical Centre, Clayton, Australia; 7Hôpital Cochin, Paris, France; 8Gallipoli Medical Research Foundation, Greenslopes, Australia; 9Royal Adelaide Hospital, Adelaide, Australia; 10Bristol-Myers Squibb Research & Development, Wallingford, CT; 11Bristol-Myers Squibb Research & Development, Princeton, NJ.
![AASLD1.gif](../images/112315/112315-5/AASLD1.gif)
![AASLD2.gif](../images/112315/112315-5/AASLD2.gif)
![AASLD3.gif](../images/112315/112315-5/AASLD3.gif)
![AASLD4.gif](../images/112315/112315-5/AASLD4.gif)
![AASLD5.gif](../images/112315/112315-5/AASLD5.gif)
![AASLD6.gif](../images/112315/112315-5/AASLD6.gif)
![AASLD7.gif](../images/112315/112315-5/AASLD7.gif)
![AASLD8.gif](../images/112315/112315-5/AASLD8.gif)
![AASLD9.gif](../images/112315/112315-5/AASLD9.gif)
![AASLD10.gif](../images/112315/112315-5/AASLD10.gif)
![AASLD11.gif](../images/112315/112315-5/AASLD11.gif)
![AASLD12.gif](../images/112315/112315-5/AASLD12.gif)
![AASLD13.gif](../images/112315/112315-5/AASLD13.gif)
![AASLD14.gif](../images/112315/112315-5/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|